SCIENTIFIC PUBLICATIONS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
Investor Conference Call September 9, 2020 – Presentation
To download the presentation, Click Here
Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting
Updated Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression Conference Call Today Scheduled for 5:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 – Sutro...
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting
Ongoing Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression Conference Call Scheduled for Sept 9, 2020 at 5:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020...
IGCS 2020 Annual Global Meeting – Abstract
Phase 1 Dose-Escalation Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum Resistant/Refractory Epithelial Ovarian Cancer (OC). Dr. Naumann is currently the Director of Minimally Invasive Surgery in...
Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
SOUTH SAN FRANCISCO, Calif., August 10, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Bristol Myers Squibb Investor Series
June 25, 2020 at 11:30am ET WEBCAST View This Presentation June 22, 2020 at 11:30am ET WEBCAST View This Presentation
M1231: A First In-Class Bispecific ADC Targeting EGFR and MUC1 Presented by EMD Serono at American Association for Cancer Research (AACR) Virtual Meeting II on June 24, 2020 – Presentation
AACR requires pre-registration to access this presentation. Oral Presentation & Discussion, timestamp 1:43:36, expired link no longer available
American Association for Cancer Research (AACR) 2020 Virtual Meeting II – Abstract
STRO-002, An Anti-FolRα ADC, Demonstrates Immune-Modulating Properties and Potentiates PD-L1 Blockade Millicent Embry*, Sihong Zhou*, Christine Cheng, Janice Yu, Cristina Abrahams, Xiaofan Li, Jeff Hanson, Cuong Tran, Gang Yin, Shamim Ahmad, Krishna Bajjuri, Venita...
American Association for Cancer Research (AACR) 2020 Virtual Meeting II – Poster
STRO-002, An Anti-FolRα ADC, Demonstrates Immune-Modulating Properties and Potentiates PD-L1 Blackade Please Click the Link, STRO-002 AACR 2020 Poster to Enlarge Please click link to view, Poster Script Please click play button below to listen, Poster Narrative